XERS

Gvoke®

Severe Hypoglycemia

Stage (next event)

Expected Date

Quarterly Sales (Approved)

March 12, 2021 (Est)

Catalyst Info & Data Links

TITLE: Gvoke® for Severe Hypoglycemia  - Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Quarterly sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • March 21, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE


Quarter's sales: $9.4M (Q3/2020)

2020 Revenue guidance: NOT PROVIDED by company

Mechanism of Action

MECHANISM OF ACTION

  • Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.

MARKET

  • There are 22.1M persons with diabetes in the US (T1D & T2D), where 6.2M currently use insulin

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon